Investing.com - Quest Diagnostics (NYSE: DGX) reported third quarter EPS of $2.30, $0.04 better than the analyst estimate of $2.26. Revenue for the quarter came in at $2.49B versus the consensus estimate of $2.43B.
Guidance
Quest Diagnostics sees FY 2024 EPS of $8.85-$8.95 versus the analyst consensus of $8.89.
Quest Diagnostics sees FY 2024 revenue of $9.80B-$9.85B versus the analyst consensus of $9.66B.
Quest Diagnostics's stock price closed at $147.37. It is up 2.16% in the last 3 months and up 21.34% in the last 12 months.
Quest Diagnostics saw 0 positive EPS revisions and 14 negative EPS revisions in the last 90 days. See Quest Diagnostics's stock price’s past reactions to earnings here.
According to InvestingPro, Quest Diagnostics's Financial Health score is "good performance".
Check out Quest Diagnostics's recent earnings performance, and Quest Diagnostics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar